Regranex Gel REGRANEX GEL diabetic foot ulcers
Professionals Home
About REGRANEX Gel
Coverage Information
Endorsements
Request a rep
Important Safety and Prescribing Information

  Home
  Healthcare Professionals
  Media Center


print page book mark email page
print page book mark email page

 
Other Johnson & Johnson Wound Management Products
Important Safety Information

REGRANEX Gel should not be used in patients with cancers at the site of application. In a safety study, patients treated with 3 or more tubes of REGRANEX Gel had an increased risk of death from cancer at locations in the body other than the ulcer. Talk to your doctor about risks of cancer and tell your doctor if you have or have had cancer.

In clinical studies, a small percentage of patients treated with REGRANEX Gel or placebo gel experienced rash near the wound. REGRANEX Gel should not be used by patients sensitive to any components of this product. Please click here to see the Full Prescribing Information for REGRANEX Gel.



Full Prescribing Information | Media Center | Legal Notice | Privacy Policy | Contact Us | Site Map




© Systagenix Wound Management (US), Inc. 2008. All rights reserved.
This site is published by Systagenix Wound Management (US), Inc. which is solely responsible for its contents.
This site is intended for U.S. audiences only.
Last Updated: 12 May 2009